Figure 1.
![Time to presentation with thrombocytopenia following the most recent dose of a SARS-CoV-2 vaccine. The graph compares vaccine type (Pfizer-BioNTech [n = 39] and Moderna [n = 37]) in persons without reported preexisting platelet disorders.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/139/10/10.1182_blood.2021013411/7/bloodbld2021013411f1.png?Expires=1722730979&Signature=SpOBN2Cx9ZSp67wwr10RAxOpOrOmlyJ5osrOx5~KPVWMU9Fx4U0xCZ20IuK-d077cQ4hhD6ZH~moCwI7jjNMRH51m~3-2BfLqbonhP0edrOr-B-BHcIX9zlQdWrLC50SazcrXiAGH7w372dFVaZ5rH8nqJYWM5J97MQCpdlaVRKrjPc2ztAUe~dhKv2qU6o9Jef9F-Pw9zxYr6hXJGHIIBvXTEbiO617B4lzk8W57FCdxApPxCefLEz2dYfexIv90~z6mv~eDPRfO7d9F2g3NuXSciwBjrkTVXarK22z6vrJOOBKkyeo0q4QiFrNvEOWHX-tupVWsOcUMyiVTaj4xw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Time to presentation with thrombocytopenia following the most recent dose of a SARS-CoV-2 vaccine. The graph compares vaccine type (Pfizer-BioNTech [n = 39] and Moderna [n = 37]) in persons without reported preexisting platelet disorders.
Time to presentation with thrombocytopenia following the most recent dose of a SARS-CoV-2 vaccine. The graph compares vaccine type (Pfizer-BioNTech [n = 39] and Moderna [n = 37]) in persons without reported preexisting platelet disorders.